Accuracy of stellar parameters of exoplanet-host stars determined from asteroseismology

In the context of the space-based mission CoRoT, devoted to asteroseismology and search for planet transits, we analyse the accuracy of fundamental stellar parameters (mass, radius, luminosity) that can be obtained from asteroseismological data.} Our work is motivated by the large uncertainties on planetary radius determination of transiting planets which are mainly due to uncertainties on the stellar parameters. Our goal is to analyse uncertainties of fundamental stellar parameters for a given accuracy of oscillation frequency determination. We generate grids of equilibrium models of stars and compute their pulsation spectra based on a linear nonadiabatic stability analysis. Using differents methods of comparison of oscillation mode spectra, we derive uncertainties on fundamental stellar parameters and analyse the effect of varying the number of considered modes.} The limits obtained depend strongly on the adapted method to compare spectra. We find a degeneracy in the stellar parameter solutions, up to a few % in mass (from less than 1% to more than 7% depending on the method used and the number of considered modes), luminosity (from 2% to more than 10%) or radius (from less than 1% to 3%), for a given pulsation spectrum.Comment: 7 pages, 9 figure

UNRMS Case Study: A Circular and Servitized Approach to Resource Management in the UK

This is the final version. Available from UNECE via the links in this recordPresentation on a circular and servitized approach to resource management, using the example of Southwest England in the context of the renewed exploration and development of critical metal resource projects. Presented at the UNECE Resource Management Week 2023: assuring sustainability in resource managementEngineering and Physical Sciences Research Council (EPSRC

Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada

Background The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary syndromes. Recently, Effient (prasugrel [Eli Lilly Canada Inc, Toronto, Canada]) was discontinued by its distributor in Canada. Methods Five members of the Canadian Cardiovascular Society antiplatelet therapy 2018 guidelines committee undertook an independent, evidence-based review to outline patients for whom prasugrel should be the optimal P2Y12 agent and discuss alternative strategies to consider without prasugrel. Results Several clinical scenarios where prasugrel should be indicated are identified and discussed. Considerations to be undertaken for alternative therapies are summarized, including a review of national and international guidelines for de-escalation of P2Y12 receptor antagonists. Conclusions The discontinuation of prasugrel poses a challenge for clinicians. Clinicians must consider key factors in determining the best alternate therapy.Introduction Dans ses lignes directrices actuelles sur la thérapie antiplaquettaire, la Société canadienne de cardiologie recommande l’utilisation du ticagrélor ou du prasugrel plutôt que l’utilisation du clopidogrel comme antagonistes des récepteurs plaquettaires P2Y12 de première intention dans le traitement des patients qui présentent un risque modéré à élevé de syndromes coronariens aigus. Depuis peu, le distributeur a cessé la distribution d’Effient (prasugrel) au Canada. Méthodes Cinq membres du comité des lignes directrices 2018 sur la thérapie antiplaquettaire de la Société canadienne de cardiologie ont entrepris une revue indépendante fondée sur les données probantes pour dresser le profil des patients pour lesquels le prasugrel devrait être la meilleure option parmi les antagonistes des récepteurs P2Y12 et se pencher sur les traitements alternatifs en l'absence de prasugrel. Résultats Plusieurs scénarios cliniques où le prasugrel devrait être indiqué sont recensés et abordés. Les réflexions sur les solutions de rechange au traitement, notamment une revue des lignes directrices nationales et internationales en matière de désescalade des antagonistes des récepteurs P2Y12, sont présentées. Conclusions La cessation de la distribution du prasugrel pose problème aux cliniciens. Les cliniciens doivent tenir compte des facteurs clés pour déterminer le meilleur traitement de remplacement

Preliminary Validation of a Mobility Obstacle Course for Persons with Mobility Impairment

The purpose of this study was to assess the reliability and validity of a mobility obstacle course for women with mobility impairments. Participants included 72 adult women with permanent physical disabilities including arthritis, orthopedic conditions, paraplegia, and others. The 60-m course consisted of carpeted runways and turns, ramps, a doorway, a transfer, and object manipulation. Participants completed two trials, walking or wheeling through the course as quickly as possible, safely and without running. Total course time and peak heart rate data were correlated with SF-36 health survey subscales. Overall, peak heart rate was significantly (p \u3c .05) correlated with physical functioning (r = -.328), limitations due to physical functioning (r = .261), and pain (r = .296). Total course time was significantly correlated with physical functioning. These findings indicate very high reliability and preliminary evidence of validity